Ipamorelin

Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) and stimulates the pituitary gland to release endogenous growth hormone in a pulsatile manner. Unlike earlier growth hormone releasing peptides, ipamorelin is highly selective and does not significantly stimulate ACTH, cortisol, or prolactin release at effective doses. After subcutaneous injection, GH levels peak within approximately 40 minutes and return to baseline by 2–3 hours. This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns. Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms[5], though cycling is recommended as a precautionary measure. Ipamorelin has also demonstrated pro-motility effects in the gastrointestinal tract via GHSR-1a receptors, with preclinical and clinical studies showing it can accelerate gastric emptying.